Sera Prognostics, Inc.

NASDAQ:SERA

Medical - Diagnostics & Research

Healthcare
$1.91 -1.59%

-$0.03 today

Market cap
$74.11M
Beta
0.94
P/E (TTM)
-2.9
EPS (TTM)
-$0.64
52W Low $1.56High $4.09

Volume 0.01M

Average 0.06M

SERA Net Income

Bottom-line profit after all expenses, interest, and taxes.

Sera Prognostics, Inc.NASDAQ: SERA

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$8.4M, compared with -$8.19M a year earlier. Trailing-twelve-month net income was -$32.14M.

Context

  • Net income amounted to 39417.3% of revenue in FY2025, down 3307.4 pp from a year earlier.
  • Net income grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 2 analysts of -$34.45M (-7.9%) for the fiscal year ending Dec 2026, a slowdown from the +2.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$8.4M-6.6% QoQ
Last fiscal yearDec 2025
-$31.93M+2.9% YoY
LTMMar 2026
-$32.14M+2.6% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.6%+2.6%+5.2 pp
1 year+2.9%-7.9%-10.8 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(31.93M) USD
Year-over-year change
+2.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How SERA compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +2.6% is the 4th highest of 9, against a peer median of -16.0%.
  • Net income amounts to 56386.0% of revenue for SERA, versus a peer median of 876.7%.
SERA Competitors
Net Income for SERA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
APYXApyx Medical CorporationLTM Mar 2026-$9.17M USD+54.2%—16.4%
CGTXCognition Therapeutics, Inc.LTM Mar 2026-$19.58M USD+41.2%——
HURATuHURA Biosciences, Inc.LTM Mar 2026-$30.93M USD-50.4%——
SERASera Prognostics, Inc.LTM Mar 2026-$32.14M USD+2.6%—56386.0%
ONCYOncolytics Biotech Inc.LTM Mar 2026-CA$35.52M CAD-20.2%——
LUCDLucid Diagnostics Inc.LTM Mar 2026-$45.01M USD+27.2%—876.7%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026-$50.14M USD-11.8%—145.8%
SRZNSurrozen, Inc.LTM Mar 2026-$342.56M USD-319.3%—4571.1%
STSSSkyAI, Inc.LTM Mar 2026-$370.67M USD-5705.3%—93391.3%
Peer median (excluding SERA) —-16.0%—876.7%

Competitors are the stored peer set for SERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue82K268K306K77K81K
Cost of Revenue37K193K210K82K164K
Gross Profit45K75K96K(5K)(83K)
Gross Margin54.9%28.0%31.4%-6.5%-102.5%
Research & Development11.02M14.24M15.23M14.73M13.17M
Selling, General & Admin24.42M31.48M24.69M21.9M23.25M
Operating Expenses35.44M45.73M39.92M36.63M36.42M
Depreciation & Amortization659K756K900K833K940K
EBITDA(33.6M)(43.37M)(35.29M)(32.04M)(30.98M)
EBITDA Margin-40980.5%-16182.5%-11531.7%-41606.5%-38245.7%
Operating Income(35.4M)(45.65M)(39.82M)(36.64M)(36.5M)
Operating Margin-43164.6%-17034.3%-13013.4%-47577.9%-45066.7%
Interest Income145K456K1.64M2.75M4.59M
Interest Expense746K61K55K28K9K
Other Income / Expenses386K1.47M3.58M3.74M4.58M
Income Before Tax(35.01M)(44.19M)(36.24M)(32.9M)(31.93M)
Pre-Tax Margin-42693.9%-16487.3%-11843.8%-42724.7%-39417.3%
Income Tax Expense00000
Net Income(35.01M)(44.19M)(36.24M)(32.9M)(31.93M)
Net Margin-42693.9%-16487.3%-11843.8%-42724.7%-39417.3%
EPS (Basic)(1.18)(1.43)(1.16)(0.99)(0.67)
EPS (Diluted)(1.18)(1.43)(1.16)(0.99)(0.67)
Weighted Avg Shares30.77M30.94M31.2M33.16M47.66M
Weighted Avg Shares (Diluted)30.77M30.94M31.2M33.16M47.66M

Sera Prognostics, Inc.

NASDAQ:SERA

Intrinsic Alpha fair value

Locked

Current Price

$1.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.